PRESS RELEASE AUGUST 2022
AFRIGEN and ABM Africa
Agribiomed (ABM) Africa has secured an exclusive license for Afrigen’s proprietary encapsulation technology for Cannabidiol (CBD) oil in the EU, UK and EEC. The technology makes CBD water soluble, and therefore up to 15 times more readily absorbable by the human body, boasting a faster molecular onset of physiological action than regular forms of CBD oil. Using this technology has the benefit of unlocking significantly greater bioavailability, and thus a dramatically enhanced therapeutic effect.
A supplementary clinical bioavailability study using Afrigen’s technology is currently underway at an accredited EU clinical trial facility, and the results are due for release in Q3 2022. ABM’s Medical Director has been acting as expert consultant for the study.
Furthermore, ABM Africa has agreed to contract Afrigen in the interim, to manufacture encapsulated bulk CBD actives at their facility in Cape Town, South Africa.
Rajen Naidoo, commercial executive at Afrigen, says, “This is a significant milestone for Afrigen, and the relationship bears testimony to Afrigen’s investment in developing and commercialising world class encapsulation technologies, backed by real science. Furthermore, by partnering with ABM, a high tech, organic medical cannabis cultivator and processor – and a leader in the global Cannabis industry – we are confident that our technology is in excellent hands, to bring the best CBD products into these regions.”
Globally, consumers are becoming increasingly more health conscious, and expect technologically superior products that offer multiple benefits fast. Bioavailability refers to how easily a drug or substance can be used by the body, in order to have the desired clinical outcome. Naturally, greater bioavailability means more of the ‘active ingredient’ can be more easily absorbed and used, which translates into a more efficient and impactful healing process for the consumer.